Vaximm

Vaximm specializes in developing active immunotherapies, specifically oral T-cell vaccines, for cancer patients. The company's lead product candidate, VXM01, aims to target the tumor vasculature, a critical component for tumor growth beyond microscopic size. Vaximm's innovative approach utilizes modified attenuated bacteria as first-in-class oral T-cell activators, allowing for flexible targeting of various cancer-related antigens. Preclinical studies have demonstrated significant anti-tumor activity, and Vaximm is poised to advance into human clinical trials, marking a significant step in offering advanced treatment options for cancer patients.